Humacyte
PublicHumacyte is now publicly traded
The data on this page reflects Humacyte's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Debt
Dec 16, 2025
Total Funding Raised
$696.15M
Company Overview
Humacyte (NAS: HUMA) is a biotechnology company focused on creating universally implantable bioengineered human tissues and organs to enhance patient outcomes and revolutionize medical practices.
Sector
Biotech
AI Layer
Non-AI
Keywords
Humacyte Comparables
Compare Humacyte with similar companies based on industry and business-model similarity.
Humacyte Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Dec 16, 2025 | ||||
| Private Placement | Oct 8, 2025 | ||||
| Debt | May 12, 2023 | ||||
| Reverse Merger | Aug 26, 2021 | ||||
| Strategic | Jun 11, 2018 | ||||
Grant | Sep 28, 2017 |
Humacyte Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Access Industries | Series B |
| U.S. Department of Defense | Grant |
| Avenue Capital Group | Debt |
| UBS O'Connor | Reverse Merger |
| OrbiMed | Reverse Merger |
| Bangkok Bank | Series B |
| California Institute for Regenerative Medicine | Grant |
Humacyte Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access